EGFR and lung carcinoma: Unfortunately, when the IGF1R inhibitor linsitinib was combined with erlotinib in EGFR-mutated lung cancer patients, the PFS, ORR, and disease control rate were lower in the combination group compared to the erlotinib monotherapy group [246].